Screener
Ionis Pharmaceuticals IONS Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of deferred contract revenue | 73,837 | 73,761 |
| Other current liabilities | 25,149 | 22,738 |
| Total current liabilities | 315,638 | 781,567 |
| Long-term deferred contract revenue | 63,030 | 92,001 |
| 0 percent convertible senior notes due 2030, net | 753,356 | 751,495 |
| 1.75 percent convertible senior notes due 2028, net | 569,255 | 567,830 |
| Liability related to sale of future royalties, net | 562,574 | 551,353 |
| Long-term lease liabilities | 262,476 | 262,383 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's contract liabilities, non-current?
- Ionis Pharmaceuticals (IONS) reported contract liabilities, non-current of $63.03M in Q2 2026.
- How has Ionis Pharmaceuticals's contract liabilities, non-current changed year-over-year?
- Ionis Pharmaceuticals's contract liabilities, non-current decreased by 49.6% year-over-year, from $125.1M to $63.03M.
- What is the long-term trend for Ionis Pharmaceuticals's contract liabilities, non-current?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's contract liabilities, non-current has grown at a -26.3% compound annual growth rate (CAGR), from $424.05M to $92M.
Ask your AI about Ionis Pharmaceuticals's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude